Manuscript Number not assigned

Article Summary Line: The risk of infection with SARS-CoV-2 in a vaccinated cohort associated with a private festive event was significantly increased upon conversation with the putative index person and positively correlated to the duration of stay at the event.

Running Title: COVID-19 outbreak in Northern-Bavaria, Germany 2021

Keywords: COVID-19, SARS-CoV-2, outbreak, breakthrough infection

Breakthrough Infections with SARS-CoV-2 in Vaccinated Students After a Festive Event – Identification of Risk Factors

Ralph Bertram¹, Vanessa Bartsch², Johanna Sodmann², Luca Hennig², Engin Mjude², Jonathan Stock², Vivienne Ruedig², Philipp Sodmann³, Daniel Todt^{4,5}, Eike Steinmann⁴, Wolfgang Hitzl^{6,7,8}, Joerg Steinmann¹

¹ Institute of Clinical Hygiene, Medical Microbiology and Infectiology, Klinikum Nürnberg, Paracelsus Medical University, Nuremberg, Germany

² Paracelsus Medical University, study program in human medicine, Nuremberg, Germany

³ Department of Internal Medicine II, University Hospital Würzburg, Wuerzburg, Germany

⁴ Department of Molecular and Medical Virology, Ruhr-Universität Bochum, Bochum, Germany

⁵ European Virus Bioinformatics Center (EVBC), Jena, Germany

⁶ Department of Research and Innovation Management, biostatistics and publication of clinical trial studies, Paracelsus Medical University, Salzburg, Austria

⁷ Paracelsus Medical University Salzburg, Department of Ophthalmology and Optometry,
Salzburg, Austria

⁸ Research Program Experimental Ophthalmology and Glaucoma Research, Paracelsus Medical
University Salzburg, Austria

Correspondence: Joerg Steinmann, Email: joerg.steinmann@klinikum-nuernberg.de, Phone:
+49 911 398 2520

ORCID: Ralph Bertram: 0000-0003-0654-6381; Vanessa Bartsch: 0000-0001-6029-2103;
Daniel Todt: 0000-0002-3564-1014; Eike Steinmann: 0000-0002-3654-9965; Wolfgang Hitzl:
0000-0002-7696-1479; Joerg Steinmann: 0000-0002-3181-3667;

Abstract—word count: 49

We report an outbreak with SARS-CoV-2 breakthrough infections related to a festive event
in Northern Bavaria, Germany in October 2021, with 24 of 95 participants infected. Correlation
analyses among 15 interrogated variables revealed that duration at the event and conversation with
the supposed index person were significant risk factors.

Text—word count: 1235

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the etiologic
agent of the Coronavirus disease 2019 (COVID-19), classified as pandemic by the WHO on
March 11, 2020 (<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>). COVID-
19 outcomes range from asymptomatic to multifactorial with fatality rates of around 1.5-2% in
developed countries (<https://www.statista.com/statistics/1105914/coronavirus-death-rates->

[worldwide/](#)). SARS-CoV-2 is largely transmitted airborne, by aerosols and droplets (1). A viral load up to ~3,000 SARS-CoV-2 particles has been reported in 1 L of exhaled breath of infected individuals (2), with an infectious dose as low as 10 aerosol-borne SARS-CoV-2 particles (3). Airborne transmission is positively correlated to proximity and duration of unprotected contacts to infected individuals (4). Accordingly, non-pharmaceutical prevention interventions include medical-grade face masks, handy hygiene, social distancing and ventilation of indoor spaces (5). Safe and effective vaccines have a game-changer potential against the COVID-19 pandemic. As of November 2021 four vaccines against SARS-CoV-2 have been approved by the European Medicines Agency (<https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-covid-19/treatments-vaccines/vaccines-covid-19/covid-19-vaccines-authorised#authorised-covid-19-vaccines-section>). These are viral vectors (AZD1222, AstraZeneca and JNJ-78436735, Johnson&Johnson) or lipid contained mRNA (BNT162b2, BioNTech/Pfizer and mRNA-1273, Moderna). The vaccines target the spike protein, critical for viral entry into host cells. SARS-CoV-2 variant B.1.617.2 (delta variant), which bears at least 6 characteristic mutations in spike (6), was the predominant variant in Germany in November 2021 (https://www.rki.de/DE/Content/InfAZ/N/Neuartiges_Coronavirus/DESH/Berichte-VOC-tab.html). (Super)spreader events are serious drivers of the COVID-19 pandemic (7-10). We here report on an outbreak of SARS-CoV-2 in fully vaccinated students associated with a private festive event in October 2021 in Northern Bavaria, Germany, and shed light on factors associated with elevated risk of infection.

The study

The event took place in Northern Bavaria, Germany, in October 20, 2021 with a duration of about 8h in a poorly ventilated room of about 85 m² and a garage with less traffic. Exactly 100 students were sojourning at the location. Access was limited to those vaccinated, recovered or tested negative for SARS-CoV-2 by either PCR or antigen point-of-care test (AgPOCT) before (online Technical Appendix Table 1). Participants neither wore face masks nor practiced social distancing during the event. All further descriptions and calculations pertain to 95 persons (95%) who provided data associated with the event.

Participants were 53 males (56%) and 42 females (44%). In the aftermath of the event, 24 (25%) were diagnosed positive for SARS-CoV-2 (online Technical Appendix Table 2). All of the PCR verified isolates were of the delta type and 8 of them were sequenced. Seven were of the B.1.617.2 lineage and one of the AY.122 (B.1.617.2.122) lineage. Eight persons, all fully vaccinated, reported COVID-19 symptoms at the beginning of the event. Two of them took an AgPOCT less than 24 hours prior to the event and tested negative. Of the remaining 6, person 1.2 was diagnosed positive by AgPOCT at day 1 and PCR (cycle threshold = 24) at day 2 after the event. Thus, 1.2 as regarded as one probable index person. A proximity warning app (<https://www.coronawarn.app/en/>) was used by 59 of the participants and gave a posteriori alert in 52 cases (88%). Fifteen of the positively tested had used the app and 13 of them (87%) had received warning. Four of the participants had recovered from a COVID-19 infection previously. All of them had received 1 to 3 vaccinations post infection. One individual was neither recovered nor vaccinated but tested negative by AgPOCT at the day of the event. The other 90 individuals were vaccinated with 1 to 3 jabs with homologous and heterologous vaccination regimes. The periods of the last administered vaccination ranged from 15 days to 269 days (mean: 142 days, median: 141 days) before the event. Overall, 53 (56%) featured 1 or 2 risk factors for severe

COVID-19. The participants attended the event for 60 to 510 min (mean 268 min, median 285 min). At least 89 guests were at the venue simultaneously with the supposed index person. Persons reported contacts with 4 – 80 other guests (mean 19.2, median 16). Figure 1 provides an overview of contact among all participants (Figure 1, panel A), or only between those tested positive after the event (Figure 1, panel B). Interactive graphs provide contact profiles for each single participant or each infected person (online Technical Appendix, URL 1 and URL 2). In all, 36 participants reported conversation with the index person. None of the infected persons required hospitalization. However, 22 reported between one and eight symptoms (online Technical Appendix Figure 1), with runny nose (n=19), headache (n=16) and loss of smell (n=14) being most prevalent. One month after the event, 10 persons reported on continued symptoms of decreased endurance or impaired sense of smell.

In search of risk factors for SARS-CoV-2 infection associated with the event, we analyzed possible correlations between interrogated variables (see supplemental material) and infection. Three correlations were significant:

- i) Elongated stays at the event (Figure 2; online Technical Appendix Figure 2) (*t*-test, *p* = 0.0002). Notably, none of the guests that stayed 210 min or less was tested positive.
- ii) Conversation with the supposed index person. Of the 24 infected persons, 13 (54%) had talked to the person. This translates to a risk of infection of 36% compared to 17% without conversation (Fisher's Exact, two-sided, *p* = 0.0497).
- For participants staying ≥ 3 h, we calculated risks of infection of 25% (without conversation) and 38% (with conversation with the index).
- iii) The risk of infection was significantly lower upon heterologous vaccination with AZD+BNT (23%) than with AZD+AZD (60%) (Fisher's Exact, two-sided, *p* = 0.0489)

In addition, the following non-significant observations were found:

- Risk of infection appeared decreased with BNT+BNT compared to AZD+AZD (Fisher's Exact, two-sided, $p = 0.14$)
- Risk of infection appeared decreased with AZD+BNT compared to BNT+BNT (Fisher's Exact, two-sided, $p = 0.57$)
- The duration since last vaccination appeared inversely correlated to protection (logistic regression model, $p = 0.38$).
- Infections of guests who shared drinking vessels were slightly increased (Fisher's Exact test, two-sided, $p = 0.24$).
- The numbers of contacts was slightly increased in infected subjects (21.6 ± 12.6) vs. subjects without infection (18.4 ± 12.6 ; generalized log-gamma model, two-sided, $p = 0.18$)

Conclusions:

Our data show an attack rate of 25% in 96% fully vaccinated students at the event. Among the 24 infected persons, 10 declared no direct contact to the putative index person. Possible explanations for their infection are, i) more than 1 index person was at place (which may be supported by the finding of one other lineage), ii) infectious particles spread through the air within the venue and accumulated above infective threshold over time, or iii) infection did not occur at the event. Our findings regarding such infection breakthroughs are consistent with reports on waned efficiencies of the currently approved vaccines in the delta surge (11, 12). Furthermore, vaccine effects decrease with time after administration (13). A three-shot vaccination regimen with BNT162b2 as a “booster” increases efficacy against delta (14, 15) and

137 accordingly, only 1 of 7 individuals (14%) with three doses of vaccine became infected in our
138 study.

139 Our data provide evidence that duration of stay at an event and conversation to index persons are
140 major risk factors for COVID-19 infection during crowded indoor events with poor ventilation.
141 Since currently available vaccines do not provide sterile immunity, high-quality testing of
142 participants should be considered a mandatory measure to avoid SARS-CoV-2 infections at
143 gatherings, irrespective of the vaccination status. Further studies that include larger cohorts are
144 required to provide insights into the interplay of risk factors for SARS-CoV-2 transmission.

146 **Acknowledgments**

147 We thank the Paracelsus Medical University for their support.

149 **Author Bio**

150 Assoc.-Prof. Dr. Ralph Bertram is a microbiologist and a researcher and lecturer in the
151 Institute of Clinical Hygiene, Medical Microbiology and Infectiology, Klinikum Nürnberg,
152 Paracelsus Medical University, Nuremberg, Germany. His research interests focus on infectious
153 diseases, drug insensitivity of nosocomial pathogens and gene regulation.

155 **References**

156 1. Prather KA, Marr LC, Schooley RT, McDiarmid MA, Wilson ME, Milton DK. Airborne
157 transmission of SARS-CoV-2. Science. 2020 10 16;370(6514):303-4.

- 158 2. Malik M, Kunze AC, Bahmer T, Herget-Rosenthal S, Kunze T. SARS-CoV-2: Viral
159 Loads of Exhaled Breath and Oronasopharyngeal Specimens in Hospitalized Patients with
160 COVID-19. *Int J Infect Dis.* 2021 Sep;110:105-10.
- 161 3. Bazant MZ, Bush JWM. A guideline to limit indoor airborne transmission of COVID-19.
162 *Proc Natl Acad Sci U S A.* 2021 04 27;118(17).
- 163 4. Farthing TS, Lanzas C. Assessing the efficacy of interventions to control indoor SARS-
164 Cov-2 transmission: An agent-based modeling approach. *Epidemics.* 2021 Nov 12;37:100524.
- 165 5. Bo Y, Guo C, Lin C, Zeng Y, Li HB, Zhang Y, et al. Effectiveness of non-
166 pharmaceutical interventions on COVID-19 transmission in 190 countries from 23 January to 13
167 April 2020. *Int J Infect Dis.* 2021 Jan;102:247-53.
- 168 6. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. The
169 biological and clinical significance of emerging SARS-CoV-2 variants. *Nat Rev Genet.* 2021
170 12;22(12):757-73.
- 171 7. Correa-Martínez CL, Kampmeier S, Kumpers P, Schwierzeck V, Hennies M, Hafezi W,
172 et al. A Pandemic in Times of Global Tourism: Superspreading and Exportation of COVID-19
173 Cases from a Ski Area in Austria. *J Clin Microbiol.* 2020 05 26;58(6).
- 174 8. Hamner L, Dubbel P, Capron I, Ross A, Jordan A, Lee J, et al. High SARS-CoV-2 Attack
175 Rate Following Exposure at a Choir Practice - Skagit County, Washington, March 2020.
176 *MMWR Morb Mortal Wkly Rep.* 2020 May 15;69(19):606-10.
- 177 9. Muller N, Kunze M, Steitz F, Saad NJ, Mühlemann B, Beheim-Schwarzbach JI, et al.
178 Severe Acute Respiratory Syndrome Coronavirus 2 Outbreak Related to a Nightclub, Germany,
179 2020. *Emerg Infect Dis.* 2020 02;27(2):645-8.

- 180 10. Streeck H, Schulte B, Kümmerer BM, Richter E, Höller T, Fuhrmann C, et al. Infection
181 fatality rate of SARS-CoV2 in a super-spreading event in Germany. Nat Commun. 2020 11
182 17;11(1):5829.
- 183 11. Lopez Bernal J, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al.
184 Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant. N Engl J Med. 2021
185 08 12;385(7):585-94.
- 186 12. Hacisuleyman E, Hale C, Saito Y, Blachere NE, Bergh M, Conlon EG, et al. Vaccine
187 Breakthrough Infections with SARS-CoV-2 Variants. N Engl J Med. 2021 06 10;384(23):2212-
188 8.
- 189 13. Nordström P, Ballin M, Nordström A. Effectiveness of Covid-19 vaccination against risk
190 of symptomatic infection, hospitalization, and death up to 9 months: a Swedish total-population
191 cohort study. Preprints with The Lancet; 2021.
- 192 14. Barda N, Dagan N, Cohen C, Hernán MA, Lipsitch M, Kohane IS, et al. Effectiveness of
193 a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in
194 Israel: an observational study. Lancet. 2021 Oct 29.
- 195 15. Bar-On YM, Goldberg Y, Mandel M, Bodenheimer O, Freedman L, Kalkstein N, et al.
196 Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel. N Engl J Med. 2021 10
197 07;385(15):1393-400.

198

199

200

201

202

Figures and Legends

Figure 1A. Overview of interactions between participants at the event. Each guest is represented by a node and all interactions longer than 10 minutes and a distance less than 1.5 m away are represented as edges between the nodes. The color of the nodes represents test results after the event, red indicating infection, green: no infection detected, grey: unknown. The blue node represents the putative index. To create the visualization, each node started at a random position. The spacing on the diagram and the dimensions of the axes are arbitrary.

211 **Figure 1B.** Contacts between individuals tested positive after the event. Coloring scheme as in
212 Fig. 1A.

213

214

215

216

217

218

219 **Figure 2.** Box and whisker plot of the duration at the event in relation to a positive or negative
 220 test. Duration of exposition was significantly higher in subjects with positive tests (*t*-test, two-
 221 sided, $p=0.0002$)